+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID00722228

Study of Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Melanoma and Various Epithelial Cancers

Led by Hadassah Medical Organization · Updated on 2025-10-02

50

Participants Needed

1

Research Sites

95 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new approach to stimulate the immune response in patients with metastatic cancers, including melanoma, colorectal, gastric, ovarian, breast, lung, and kidney epithelial cancers. This study is based on modifying tumor cells grown in the laboratory to make them stimulatory to the immune system. The goal is to assess whether this treatment can prolong survival in patients with these advanced cancers. The treatment involves injecting patients with tumor cells that have been modified and irradiated to kill them. Patients will receive five vaccine doses, each given subcutaneously at three-week intervals. These doses consist of irradiated and DNP-conjugated tumor cells, designed to activate the immune system against the cancer. Participants will be involved in receiving the vaccine injections at specified intervals. They must meet specific health criteria, including certain blood counts and organ function levels. Throughout the study, patients will be monitored for their clinical performance and response to the treatment. The study expects to follow participants and evaluate their health outcomes over time, with the overall aim of measuring the treatments impact on survival and immune activation.

CONDITIONS

Brief Title

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

Research Team

H

Hani Steinberg, R.N. B.A.

T

Tamar Peretz, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here